DUBLIN, Oct. 22, 2024 (Globe Newswire) — The “Neurological Therapeutics – Global Strategic Business Report” report has been added to ResearchAndMarkets.com’s offering.
The global market for drugs to treat neurological diseases is estimated to be USD 116.4 billion in 2023 and is projected to reach USD 149.7 billion by 2030, growing at a CAGR of 3.7% from 2023 to 2030. This comprehensive report provides a detailed analysis of the market. Understand trends, drivers, and forecasts to help you make informed business decisions.
The growth of the neurological disease therapeutics market is driven by several factors. First, the increasing prevalence of neurological diseases, especially among the elderly, has increased the demand for effective treatments. Second, advances in biotechnology and pharmaceutical research are continually leading to the development of new and improved treatments, such as gene therapy and neuroprotective agents. Expansion of medical infrastructure in emerging markets has facilitated access to neurological care, contributing to market growth.
Additionally, strategic collaborations between pharmaceutical companies, academic institutions, and research institutions are accelerating the discovery and commercialization of innovative treatments. The rise of digital health technologies such as telemedicine and wearable devices will enhance patient monitoring and management, resulting in better treatment outcomes. Finally, increased funding for neurological research and the development of comprehensive treatment guidelines are promoting a more structured and effective approach to managing neurological disorders.
Key insights:
Market Growth: Understand the significant growth trajectory of the anticholinergic drug class, expected to reach USD 45.2 billion by 2030 at a CAGR of 4.0%. The painkiller class segment is also expected to grow at a CAGR of 4.4% during the analysis period. Regional Analysis: Gain insight into the US market, estimated at $31.7 billion in 2023, and China, which is expected to grow at an impressive CAGR of 7.0%. $31.3 billion by 2030. Check out growth trends in other key regions such as Japan, Canada, Germany, and Asia Pacific.
Report features:
Comprehensive market data: Independent analysis of annual sales and market forecasts (USD million) from 2023 to 2030. Detailed regional analysis: Detailed insights into key markets including the US, China, Japan, Canada, Europe, Asia Pacific, and Latin. America, Middle East, Africa. Company Profile: Covers major companies such as AstraZeneca PLC, Biogen, Inc., and Biohaven, Ltd. Free updates: Receive 1 year of free report updates to stay informed. Market development.
Answers to key questions:
How is the global Neurology Drugs market expected to evolve by 2030? What are the key drivers and restraints impacting the market? Which market segments will grow the most during the forecast period? How will the market share of different regions and segments change by 2030? Who are the key players in the market and what is its future prospects?
Key attributes:
Report attribute details No. Number of pages 289 Forecast period 2023 – 2030 Estimated market value in 2023 (USD) 116.4 billion dollars Predicted market value by 2030 (USD) 149.7 billion dollars Average annual growth rate 3.7% Target region World
Main topics covered:
Market overview
Influencer Market Insights Global Market Trajectory Global Economic Updates Neurological Disease Treatments – Percentage Market Share of Major Competitors in the World in 2024 (E) Competitive Market Presence – Global in 2024 Powerful/Active/Niche/Mediocre for Medium Players (E)
Market trends and drivers
Rising prevalence of neurological diseases drives demand for therapeutics Advances in neurological therapeutics drive market growth Growing awareness of neurological health expands addressable market opportunities Development of precision medicine and targeted therapies Innovations in neurostimulation and neuromodulation therapies drive market interest Strengthening business case Developments in regenerative medicine and stem cell therapies drive market growth
Focus on carefully selected players (86 players in total)
AstraZeneca PLCBiogen, Inc.Biohaven, Ltd.Eisai Co., Ltd. H. Lundbeck A/SIonis Pharmaceuticals, Inc.Mitsubishi Tanabe Pharma Co., Ltd.Neurelis, Inc.Neurocrine Biosciences, Inc.Neurona Therapeutics, Inc.Ovid Therapeutics, Inc.Pfizer, Inc. Sanofi SAUCB SAVoyager Therapeutics, Inc.
For more information about this report, please visit https://www.researchandmarkets.com/r/g03pik.
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source of international market research reports and market data. We provide the latest data on international and regional markets, key industries, top companies, new products and latest trends.
Global neurological disease treatment drug market
